<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1909">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136313</url>
  </required_header>
  <id_info>
    <org_study_id>1211477</org_study_id>
    <nct_id>NCT05136313</nct_id>
  </id_info>
  <brief_title>Healthy vs Unhealthy Obesity: Mehanistic Insights and Effects of Time-Restricted Eating</brief_title>
  <official_title>Healthy vs Unhealthy Obesity in Young Male Adults: Early Predictors, Mechanistic Insights and Effects of Time-Restricted Eating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Nutrición y Tecnología de los Alimentos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agencia Nacional de Investigación y Desarrollo, ANID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Católica del Maule</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Nutrición y Tecnología de los Alimentos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity-related cardiometabolic diseases are now a leading cause of death worldwide. These&#xD;
      diseases result from a dysfunctional adipose tissue (AT) that induces inflammation, insulin&#xD;
      resistance and altered endocrine function. However, not all obese people develop metabolic&#xD;
      complications, which has given rise to the concept of &quot;metabolically healthy obesity&quot; (MHO).&#xD;
      Recent evidence suggests that intermittent fasting methods, in particular time-restricted&#xD;
      eating (TRE) may be effective in improving cardiometabolic health, independently of weight&#xD;
      loss, and this could be particularly effective in MUO subjects. We hypothesize that in young&#xD;
      male adults TRE is a more effective/beneficial approach in MUO than in MHO due to the weight&#xD;
      loss-independent improvement in their inflammatory and metabolic derangements. To this aim,&#xD;
      we will perform a 16-week 8h TRE intervention study in MHO and MUO subjects and assess&#xD;
      anthropometric, endocrine, and other outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although clinical differences between metabolically healthy and unhealthy obesity (MHO and&#xD;
      MUO, respectively) have been extensively described, cellular mechanisms involved in these&#xD;
      different phenotypes are largely unknown. This evidence is crucial for proposing preventive&#xD;
      and therapeutic approaches. Recently, intermittent fasting methods, in particular&#xD;
      time-restricted eating (TRE, a self-selected daily limited eating window protocol), have&#xD;
      shown to be effective in improving cardiometabolic health, independently of weight loss,&#xD;
      which could be particularly relevant in MUO.&#xD;
&#xD;
      We will recruit young (20-22y-old) males with obesity (BMI≥30) and classify them as MHO or&#xD;
      MUO (≤1 or ≥3 metabolic syndrome risk factors, respectively). We will conduct a 16-week, 8h&#xD;
      TRE intervention in MHO vs. MUO subgroups, to assess and compare the anthropometric,&#xD;
      metabolic, endocrine, inflammatory and peripheral blood mononuclear cell (PBMC)&#xD;
      mechanistic/signaling response&#xD;
&#xD;
      . We expect to advance the understanding of cellular mechanisms implicated in MHO and MUO,&#xD;
      including potential therapeutic targets. Ultimately, we expect to find relevant opportunities&#xD;
      for intervention to prevent the serious cardiometabolic consequences of obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TRE intervention comparing MHO vs MUO</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TG</measure>
    <time_frame>16 weeks</time_frame>
    <description>Fasting triglycerides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metabolically Healthy Obesity</condition>
  <condition>Intermittent Fasting</condition>
  <arm_group>
    <arm_group_label>MHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metabolically healthy obese subjects undergoing TRE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metabolically unhealthy obese subjects undergoing TRE</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Time-restricted eating</intervention_name>
    <description>16 weeks of TRE consisting of an 8-hour eating window.</description>
    <arm_group_label>MHO</arm_group_label>
    <arm_group_label>MUO</arm_group_label>
    <other_name>Time-restricted feeding</other_name>
    <other_name>Intermittent fasting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: belong to the GOCS cohort at INTA, BMI≥30, own and use a Smartphone&#xD;
        with Apple iOS or Android OS, baseline eating period ≥ 13 h per day.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria: medications for any metabolic syndrome disorder, shift workers, known&#xD;
        inflammatory and/or rheumatologic disease, history of cardiovascular event, thyroid or&#xD;
        adrenal disease, history of malignancy, diabetes, eating disorder, special diet (e.g.,&#xD;
        celiac disease),or any other disease or treatment that may interfere with the study.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Cifuentes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Chile INTA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Cifuentes, PhD</last_name>
    <phone>56229781428</phone>
    <email>mcifuentes@inta.uchile.cl</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Nutrición y Tecnología de los Alimentos</investigator_affiliation>
    <investigator_full_name>Mariana Cifuentes</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Time restricted eating</keyword>
  <keyword>Metabolic health</keyword>
  <keyword>PBMC</keyword>
  <keyword>Adipokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Metabolically Benign</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

